Heidelberg-based MedTech company Precisis GmbH, which specialises in neuromodulation therapies, has appointed Karl Stoklosa as its new CEO, effective September 1, 2024. Previously, Stoklosa held various leadership positions at Abbott Laboratories, most recently serving as Director of Global Marketing for the CRM Division. He succeeds Angela Liedler, who has successfully led the company since its early years.
Founded in 2014, Precisis has established itself as an innovator with the EASEE® brain pacemaker, a minimally invasive solution for the treatment of epilepsy. The company combines cutting-edge technology with a deep understanding of the needs of patients and healthcare professionals.
With a clear focus on core markets in the UK, Europe and the USA, Precisis aims to improve the quality of life for people worldwide. Stoklosa’s appointment marks the beginning of a new phase for the Heidelberg-based company, which has already established itself with the EASEE® brain pacemaker.
Dr. Felix Baader, Chairman of the Advisory Board at Precisis said, “With Karl Stoklosa at the helm, we are setting a clear course for the future of Precisis. He brings not only extensive international experience but also the vision and determination needed to take our company to the next level.”
More from News
- Bank Of England Holds Interest Rates At 4.25%, What Does This Mean For UK?
- One Of The Largest Data Breach In History Leaked 16 Billion Passwords
- 23andMe Co-Founder Bids To Buy Back Data After Company Announces Bankruptcy
- How Is The UK Boosting The Cyber Sector?
- Starlink Is Bringing More Connectivity Options To The UK, Here’s How
- Is AI To Blame For Recent Big Tech Job Cuts?
- Experts Share: How In-App Whatsapp Ads Will Affect The Overall User Experience
- UK’s NayaOne Enters Saudi Market With AstroLabs, Launching First Fully Saudi-Hosted Fintech Platform
“The MedTech industry is evolving rapidly, and we are confident that Stoklosa will drive Precisis’s momentum forward and inspire our team.”
“This leadership change marks the end of an era characterized by the outstanding work of Angela Liedler. Under her leadership, the innovative EASEE® brain pacemaker was successfully brought to market—a milestone in epilepsy treatment. Her entrepreneurial foresight and dedication remain an inspiration to all of us,” Baader added.
Ben Fear, Precisis Area Manager in the UK said; “It’s hugely positive news to have someone of Karl’s experience join Precisis. His previous global roles within major Neuromodulation companies will undoubtedly prove to be an asset to Precisis as we continue our quest to improve the lives of patients suffering from functional brain disorders, with our truly innovative EASEE system.”
Karl Stoklosa speaking about his new role said, “It is a privilege to take on the leadership of Precisis at such an exciting time. Our goal is to improve the quality of life for millions of epilepsy patients worldwide through groundbreaking technologies.
“I am determined to further enhance Precisis’s innovative strength and set new benchmarks in neuromodulation.”
Stoklosa is a renowned global executive known for consistently steering towards success. His career has been marked by successful strategies and innovations, most recently as Director of Global Marketing at Abbott Laboratories, where he made significant contributions to the CRM Division. He holds an MBA from the prestigious University of Chicago Booth School of Business.